Personalis, Inc. reported total revenue of $69.6 million for the year ended December 31, 2025, a decrease of 18% compared to $84.6 million in 2024. The decline was primarily attributed to lower Enterprise sales, specifically a decrease of $19.5 million due to the winding down of a project with Natera. This was partially offset by a $4.3 million increase in revenue from population sequencing, representing a 58% increase. The company's net loss for 2025 was $81.3 million, consistent with the $81.3 million net loss in 2024.
The company's financial performance was influenced by several factors, including a decrease in pharma testing services revenue due to reduced clinical trial sample processing for Moderna, and the expiration of minimum volume commitments with Natera. However, clinical diagnostic revenue increased by 166% to $2.0 million, driven by higher NeXT Dx test volume and NeXT Personal Dx reimbursements. The company also secured Medicare coverage for NeXT Personal Dx for breast cancer and lung cancer surveillance, which is expected to be a key catalyst for future clinical revenue growth.
Operationally, Personalis highlighted several key achievements, including the publication of landmark TRACERx data in the journal Cell, validating the clinical importance of its ultrasensitive MRD approach. The company also published VHIO data in Clinical Cancer Research, reinforcing the clinical validity of the NeXT Personal platform across various cancer types. Clinical test volume reached 16,233 tests in 2025, a nearly 400% increase compared to 2024. As of January 31, 2026, the company had 260 employees, with over 40% holding a Ph.D. or other advanced science or medical degree.
Looking ahead, Personalis anticipates that its future performance will be affected by the adoption of ultrasensitive MRD testing, the continued development of the market for genomic-based tests, and its ability to leverage its operational infrastructure. The company expects research and development expenses to increase to support the growth of its clinical diagnostic offerings. As of December 31, 2025, Personalis had approximately $240.0 million in cash, cash equivalents, and short-term investments, which the company believes will be sufficient to meet its anticipated cash requirements for at least the next 12 months.
About Personalis, Inc.
Personalis, Inc. develops and markets advanced cancer genomic tests and services for precision oncology, including liquid biopsy and tumor profiling. Its offerings support pharmaceutical research, biomarker discovery, and clinical decision-making. Serving global markets, the company emphasizes high-sensitivity technologies, clinical evidence, and strategic collaborations to enable personalized cancer therapies and improve patient outcomes. Its business model centers on high-quality genomic testing for healthcare providers and biopharmaceutical companies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.